Bionano Genomics Inc. (BNGO)
Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary 
XMEX $
1. 15
-0.02
-1.7094%
$
13.77M Market Cap
- P/E Ratio
- Div Yield
71,000 Volume
-6.61 Eps
$ 1.17
Previous Close Want to track BNGO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
BNGO closed yesterday lower at $1.15, a decrease of -1.7094% from Thursday's close, completing a monthly decrease of -8% or -$0.1. Over the past 12 months, BNGO stock lost -25.8065%.
BNGO is not paying dividends to its shareholders.
The last earnings report, released on Mar 30, 2026, exceeded the consensus estimates by 0.81%. On average, the company has surpassed earnings expectations by 1.1667%, based on the last three reports.
Bionano Genomics Inc. has completed 2 stock splits, with the recent split occurring on Jan 27, 2025.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 1 month ago
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Zacks | 1 month ago
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Seekingalpha | 2 months ago
Bionano Genomics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SE Sima Elimelech Activest Wealth Management | 3 | $8.37 | $3.57 | -$4.8 | -57.35% |
 Kevin Bresler TD Waterhouse Canada Inc. | 5 | $12.36 | $5.95 | -$6.41 | -51.86% |
| AFI Aviso Financial Inc. Aviso Financial Inc. | 1 | $2.79 | $1.17 | -$1.62 | -58.06% |
| CQS Credential Qtrade Securities Inc. Credential Qtrade Securities Inc. | 1.73 | $309 | $2 | -$307 | -99.35% |
Bionano Genomics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | -184.77 | $5,714.7 | $219.87 | $5,494.83 | 96.15% |
Bionano Genomics Inc. (BNGO) FAQ
What is the stock price today?
The current price is $1.15.
On which exchange is it traded?
Bionano Genomics Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is BNGO.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 13.77M.
Has Bionano Genomics Inc. ever had a stock split?
Bionano Genomics Inc. had 2 splits and the recent split was on Jan 27, 2025.
Bionano Genomics Inc. Profile
| Professional Services Industry | Industrials Sector | Robert Erik Holmlin CEO | NASDAQ (CM) Exchange | 09075F404 CUSIP |
| US Country | 98 Employees | - Last Dividend | 27 Jan 2025 Last Split | 21 Aug 2018 IPO Date |
Overview
Bionano Genomics, Inc. specializes in comprehensive genome analysis software designed to assist genomics labs in the interpretation and analysis of data across various platforms, offering insightful data visualizations for easy reporting of causative variants. The company aims to advance genome analysis and understanding of genetic variations and their functions. Established in 2003 and based in San Diego, California, Bionano Genomics provides a suite of products and services that cater to the needs of the genetic research community, offering innovative solutions for structural variation analysis and genetic testing services.
Products and Services
- Saphyr - A comprehensive sample-to-result solution designed for structural variation analysis through optical genome mapping. It serves as a pivotal tool for genome analysis, allowing for a deeper understanding of genetic variation and function.
- Saphyr Instrument - A sophisticated single-molecule imager essential for the operation of the Saphyr system. It is designed to accurately capture and analyze genomic information.
- Saphyr Chip - A critical consumable that facilitates the packaging of nanochannel arrays for DNA linearization, enabling precise and efficient genome mapping processes.
- Bionano Prep Kits and DNA Labeling Kits - These kits provide the necessary reagents and protocols for extracting and labeling ultra-high molecular weight DNA, essential for the analysis performed by Saphyr.
- Saphyr and Bionano Compute Servers - Powerful computing solutions offered by the company to support the data analysis demands of the Saphyr system, ensuring efficient processing and interpretation of genomic data.
- VIA Software - An integrated system for the analysis and interpretation of genomic variants from various data sources, including microarray and next-generation sequencing. Designed for use in cytogenetics and molecular genetics, VIA software enhances the understanding of genomic data.
Additionally, Bionano Genomics provides an array of testing and laboratory services to support the diagnosis and research of genetic conditions:
- FirstStepDx PLUS - A chromosomal microarray test aimed at identifying the genetic underpinnings in individuals with autism spectrum disorder, developmental delays, and intellectual disability.
- Fragile X Syndrome (FXS) Testing Services - Specialized testing services for detecting Fragile X syndrome, a genetic condition associated with intellectual disability.
- NextStepDx PLUS - An exome sequencing test designed to identify genetic variants related to childhood development disorders, enhancing the diagnostic process.
- OGM-Dx HemeOne Testing - A service offering genetic testing for hematological conditions, utilizing optical genome mapping to provide comprehensive results.
- OGM-Dx FSHD - A genetic test catered for individuals suspected of having FSHD type 1, facilitating the diagnosis of this muscular disorder.
- OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV - Comprehensive testing services for structural variations in the genome, available for both postnatal and prenatal assessments to provide extensive insights into genetic health.
Contact Information
Address: 9540 Towne Centre Drive
Phone: 858 888 7600
Website: https://www.bionanogenomics.com
